HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Muromonab-CD3 (Muromonab CD3)

Subscribe to New Research on Muromonab-CD3

Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti).

Also Known As:

Muromonab CD3; OKT3; Cilag Brand of Muromonab-CD3; Janssen Brand of Muromonab-CD3; Ortho Brand of Muromonab-CD3; Orthoclone OKT3; Cilag Brand of Muromonab CD3; Janssen Brand of Muromonab CD3; Ortho Brand of Muromonab CD3; Monoclonal Antibody OKT3

Networked: 639 relevant articles (29 outcomes, 36 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 90489
  - Blood Proteins: 4303
    - Serum Globulins: 75
      - Immunoglobulins: 23980
        Antibodies: 92632
        Monoclonal Antibodies: 18549
        Murine-Derived Monoclonal Antibodies: 1
        Muromonab-CD3: 639
        hOKT3gamma1(Ala-Ala): 6
        hOKT3 gamma4
        monoclonal antibody huOKT3(Ala-Ala)
        Immunoglobulin Isotypes: 356
        Immunoglobulin G: 38635
        Muromonab-CD3: 639
        hOKT3gamma1(Ala-Ala): 6
        hOKT3 gamma4
        monoclonal antibody huOKT3(Ala-Ala)
    - Immunoproteins: 33
      - Immunoglobulins: 23980
        Antibodies: 92632
        Monoclonal Antibodies: 18549
        Murine-Derived Monoclonal Antibodies: 1
        Muromonab-CD3: 639
        hOKT3gamma1(Ala-Ala): 6
        hOKT3 gamma4
        monoclonal antibody huOKT3(Ala-Ala)
        Immunoglobulin Isotypes: 356
        Immunoglobulin G: 38635
        Muromonab-CD3: 639
        hOKT3gamma1(Ala-Ala): 6
        hOKT3 gamma4
        monoclonal antibody huOKT3(Ala-Ala)
  - Globulins: 334
    - Serum Globulins: 75
      - Immunoglobulins: 23980
        Antibodies: 92632
        Monoclonal Antibodies: 18549
        Murine-Derived Monoclonal Antibodies: 1
        Muromonab-CD3: 639
        hOKT3gamma1(Ala-Ala): 6
        hOKT3 gamma4
        monoclonal antibody huOKT3(Ala-Ala)
        Immunoglobulin Isotypes: 356
        Immunoglobulin G: 38635
        Muromonab-CD3: 639
        hOKT3gamma1(Ala-Ala): 6
        hOKT3 gamma4
        monoclonal antibody huOKT3(Ala-Ala)

Experts

1.	Trotter, James F: 3 articles (02/2014 - 05/2003)
2.	Almenar, L: 3 articles (10/2010 - 11/2005)
3.	Kam, Igal: 3 articles (07/2010 - 05/2003)
4.	Neumann, Ulf P: 3 articles (08/2005 - 05/2002)
5.	Neuhaus, Peter: 3 articles (08/2005 - 05/2002)
6.	Emre, S: 2 articles (11/2011 - 03/2001)
7.	Jennings, Linda W: 2 articles (10/2011 - 03/2002)
8.	Levy, Marlon F: 2 articles (10/2011 - 03/2002)
9.	Canter, Charles E: 2 articles (03/2011 - 05/2004)
10.	Salvador, A: 2 articles (10/2010 - 10/2006)

Related Diseases

1.	Infection 02/01/2005 - "Induction therapy with RATG (group V) was associated with significantly improved survival and freedom from acute rejection, BOS, and infection when compared to OKT3 induction therapy (group IV). " 02/01/2005 - "An earlier impression that RATG is superior to OKT3 induction therapy has borne true in terms of overall survival and incidence of BOS, acute rejection and infection rates. " 11/01/2009 - "However, injection of human liver-derived lymphocytes treated with IL-2/OKT3 completely prevented HCV infection. " 08/01/2001 - "The linearized rate (events/100 patient days) of all infections at 3 months was 1.55 +/- 0.28 for RATG group 1 and 2.19 +/- 0.27 for OKT3 group 1 (P = NS). " 04/01/1999 - "After exposure of patients to OKT3 an increased incidence of infections and malignancies has been reported. "
2.	Neoplasms (Cancer) 12/07/2006 - "This study identifies immunosuppression, through the use of ATG or OKT3, as a predictive factor of tumor recurrence, and confirms the prognostic value of tumor differentiation." 05/01/1999 - "A previous clinical Phase I trial examined OKT3 as an immunomodulator for the treatment of cancer. " 07/01/2015 - "In the current research, CD133 expression in primary CRC was detected by immunohistochemistry, and an asymmetric BiAb consisting of monomer of chimeric AC133 (mouse anti-human CD133 monoclonal antibody) and single chain of humanized OKT3 was developed to eradicate CD133-expressing tumor cells by arming activated T cells in vitro and in vivo. " 12/01/2002 - "The cytolytic efficiency of this antibody was comparable to that of a previously described bsAb, HEA125 x OKT3, targeting preactivated T lymphocytes against Ep-CAM-carrying tumor cells. " 03/01/2002 - "OKT3 use and rejection did not show significance in tumor development. "
3.	Delayed Graft Function 09/01/1992 - "Indirect evidence exists that a prophylactic course of OKT3 may be beneficial in immunologically high-risk patients and in patients with delayed graft function. " 02/01/1990 - "Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function." 10/01/1991 - "Reduced delayed graft function (DGF) after cadaveric kidney transplantation (CKT) with selective OKT3 induction and aggressive intraoperative management." 02/01/1990 - "We conclude that OKT3 induction provides superior results over CsA induction at doses given in renal allograft recipients with delayed graft function without a significant increase in morbidity or mortality and permits the reuse of OKT3 for treatment of rejection in most cases." 11/01/1989 - "OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function."
4.	Pulmonary Edema 02/01/2004 - "The use of OKT3 for treatment of advanced high-grade acute rejection episodes eventually can result in cytokine release and consecutive pulmonary edema. " 01/01/1994 - "Furthermore, the occurrence of pulmonary edema was directly related to OKT3 administration in 7 OKT3 patients (41%), whereas only 20 cases (24%) occurred in the extant OLT patients (p < 0.001). " 12/01/1995 - "Increased risk of pulmonary edema in diabetic patients undergoing preemptive pancreas transplantation with OKT3 induction." 04/01/1993 - "Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction." 01/01/1996 - "OKT3 nephrotoxicity might have been favored by restriction of perioperative fluid infusion to prevent pulmonary edema and by the use of very high dose (30 mg/kg) of methylprednisolone (mPDS) before the first OKT3 injection to reduce the release of cytokines. "
5.	Melanoma (Melanoma, Malignant) 01/01/1990 - "Biodistribution and plasma survival in mice of anti-melanoma monoclonal antibody cross-linked to OKT3." 08/01/1993 - "In the 16 patients with melanoma who received OKT3 plus IL-2, there was a single objective response (complete response). " 04/01/1983 - "Functional T-cell subpopulations have been evaluated in the peripheral blood of 124 melanoma patients (71 non-metastatic and 53 metastatic) using monoclonal antibodies: OKT3, OKT4, OKT8, every 2 months for 1 year. " 04/01/1995 - "A patient with renal cell cancer treated at the 600-micrograms/m2 OKT3 dose level experienced a 4-month partial remission, and two mixed responses were observed in a sarcoma and a melanoma patient treated at 100- and 400-micrograms/m2 OKT3 dose levels, respectively. " 08/01/1993 - "We performed a phase IB trial of a murine monoclonal anti-CD3 antibody (OKT3) with high-dose IL-2 in patients with advanced melanoma and renal cell carcinoma. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Antilymphocyte Serum (Anti-Thymocyte Globulin)
3.	HLA-A Antigens (HLA-A)
4.	Cyclosporine (Ciclosporin)
5.	HLA-DR Antigens (HLA-DR)
6.	DNA (Deoxyribonucleic Acid)
7.	Immunoglobulin G (IgG)
8.	Steroids
9.	Tacrolimus (Prograf)
10.	Immunoglobulins (Immunoglobulin)

Related Therapies and Procedures

1.	Homologous Transplantation (Allograft)
2.	Transplantation (Transplant Recipients)
3.	Transplants (Transplant)
4.	Kidney Transplantation
5.	Aftercare (After-Treatment)